Comparison of Coenzyme Q10 (Ubiquinone) and Reduced Coenzyme Q10 (Ubiquinol) as Supplement to Prevent Cardiovascular Disease and Reduce Cardiovascular Mortality

According to the World Health Organization (WHO), cardiovascular disease (CVD) is the leading cause of death worldwide [1]. Heart failure (HF) has been defined as a global pandemic leading to millions of deaths [2]. HF is described as clinical syndrome with symptoms and/or signs caused by a structural and/or functional cardiac abnormality and corroborated by elevated natriuretic peptide levels and/or objective evidence of pulmonary or systemic congestion [3]. During the last decades, Coenzyme Q₁₀ has been established as adjunctive therapy for CVD and HF [4].

Coenzyme Q₁₀ is a redox molecule occurring in the human body in 2 bioactive states, ubiquinone (CoQ10) as oxidised state and ubiquinol (CoQH2) as reduced state [5]. Both redox forms of Coenzyme Q₁₀ are bioactive and important for human health [6]. CoQ10 is essential for cellular adenosine phosphate (ATP) energy production [7] as it shuttles electrons from complexes I and II to complex III of the mitochondrial respiratory chain (Fig. 1). CoQH2 is an important lipid-soluble antioxidant preventing peroxidation of the low-density lipoproteins in the blood circulation [8] with additional anti-inflammatory activity [9].

Bild vergrößern

A slightly better water solubility and a lack of understanding absorption and transfer of CoQ10 and CoQH2 have led to misleading interpretations pushing CoQH2 as more bioactive form [10•]. Therefore, it is important to notice that (I) CoQH2 is very unstable [11] and under normal conditions oxidised to CoQ10 [12], (II) CoQH2 has to be oxidised to CoQ10 before it can be absorbed in enterocytes [6], (III) the bioavailability of CoQ10 and CoQH2 mainly depends on crystal dispersion status and carrier oil composition [13].

Interestingly, only CoQ10 is synthesised in the human body by way of the mevalonate pathway, an essential metabolic pathway including byproducts like cholesterol and other isoprenoids. And this shared dependence on the mevalonate pathway was the reason for focusing attention to CoQ₁₀ in CVD [14].

Recent reviews clearly approved the beneficial effect of Coenzyme Q10 supplementation in treatment and prevention of CVD in clinical trials but did not distinguish between CoQ10 and CoQH2 supplementation [15]. As comparative clinical trials are missing and misleading marketing claims are revealed [10•], a critical view comparing the effectivity of supplementation with CoQ10 and CoQH2 in CVD therapies is needed.

Our goal is to determine differences in medical application of CoQ10 and CoQH2 supplementation and evaluate the efficacy of CoQ10 and CoQH2 supplementation to prevent cardiovascular diseases. The final aim is to identify the most promising supplement to reduce cardiovascular mortality in patients with heart failure. We focused on the medical evidence that can be found in the literature.

We identified 238 randomised controlled trials for ubiquinone and 35 for ubiquinol, which were sorted by medical application. Twenty-three studies of ubiquinone and 5 of ubiquinol were included to analyse their potential to prevent cardiovascular disease. These 28 studies were compared according to the ability of the given supplements to reduce cardiovascular mortality in patients with heart failure (Fig. 2).

Bild vergrößern

Even 30 years ago, studies recorded the beneficial effect of CoQ10 supplementation alone or in combination with selenium to improve EF [16], reduce time of hospitalisation [17] and reduce cardiovascular mortality in patients with heart failure [30]. In contrast to that, clinical trial investigation on the effect of CoQH2 on patients with heart failure started much later in 2020 [39] while investigations concerning antioxidant and anti-inflammatory activity of CoQH2 have been conducted in 1993 [47, 48]. This difference in medical evidence makes it challenging to compare CoQ10 and CoQH2 supplementation according to its usage to treat patients with cardiovascular disease and heart failure. Additionally, most CoQH2 studies used much higher concentrations than CoQ10 studies. CoQ10 studies included in this research test concentrations between 60 and 300 mg/day with one exception using 400 mg/day [29]. Studies with CoQ10 with selenium additive test between 100 and 200 mg/day. In contrast to that, CoQH2 studies included test concentrations between 300 and 600 mg/day. The only CoQH2 study using 300 mg/day test concentration included only 39 patients, and no beneficial cardiovascular effects could be observed [42].

Taking a closer look at major studies including at least 200 patients reveal extreme differences between CoQ10 and CoQH2. The group of Morisco et al. [17] reported a significant reduction in hospitalisation time in a study including 641 patients with heart failure and CoQ10 supplementation of 160 mg/day. The most cited Q-SYMBIO study of Mortensen et al. [25••] included 420 patients with heart failure and applied 3 × 100 mg of CoQ10 per day. After 2 years, a significant reduced time of hospitalisation and an improved NYHA class could be recorded. And most important, the cardiovascular mortality decreased by 18% compared to placebo group. KISEL-10 studies [31••] included 443 patients and applied 200 mg of CoQ10 per day combined with 200 µg of selenium. These studies focused on long-term effects of CoQ10 on cardiovascular mortality in patients with heart failure. They recorded a decrease of cardiovascular mortality of 17.9% after 10 years [32] and of 10.6% after 12 years [35]. In contrast to that, the CoQH2 study of Pierce et al. [43•] included 216 patients and applied 600 mg of CoQH2 per day in combination with 15 g/day of ribose. They recorded improved clinical status, improved EF and reduced BNPs values, but no reduction of cardiovascular mortality. According to the higher concentration (600 mg/day instead of 200 or 300 mg/day) used in CoQH2 studies and the weaker recorded benefit for patients with heart failure, the usage of CoQ10 supplementation is recommended in therapies of heart failure and cardiovascular disease in general.

Interestingly, there are differences in clinical outcomes of CoQ10 and CoQH2 despite the fact that CoQ10 can be converted to CoQH2 and vice versa in the human body by at least five enzymes [6]. Possible reasons are a different stomach transit [49] and duodenal absorption [50]. At this point, it should be stated that more pharmacological studies are needed to provide a clear answer to this question. Mantle et al. consider that many different cell types may have the capacity to reduce CoQ10 to CoQH2 in the external cellular environment. And if this is found to be the case, then presumably any of the various cell types lining the gastrointestinal tract would be able to facilitate this conversion, and the requirement for supplemental CoQH2 to maximise absorption would be negated [6]. Finally, it has to be noted that clear differences in clinical outcomes occur between CoQ10 and CoQH2.

As detailed above, our findings go along with the literature and the biochemical description of CoQ10 and CoQH2, recording cardiovascular benefits for CoQ10 and antioxidative and anti-inflammatory properties for CoQH2 [7, 8]. It has to be noted that there is a lack of clinical relevant trials and misleading marketing claims associating CoQH2 with cardiovascular benefits [10•]. Comparing the work of Morisco et al. [17] and Q-SYMBIO, KISEL-10 studies [25••, 31••] with the study of Pierce et al. [43•] lead to the following outcomes: (I) CoQ10 supplementation alone or in combination with selenium reduced cardiovascular death in patients with heart failure. This is not recorded for CoQH2. (II) Test concentrations leading to cardiovascular benefits are much lower in CoQ10 studies than in CoQH2 studies. (III) Positive long-term effects are only observed in CoQ10 studies. In these studies, reduced cardiovascular mortality is recorded even after 12 years. Based on the existing literature, the authors recommend CoQ10 instead of CoQH2 to treat and prevent cardiovascular disease in patients with heart failure.